We are now proud to announce our partnership with TRIANNI
With the aim to offer best-in-class services to our worldwide customers, Takis has been looking for a transgenic animal platform that would allow the efficient generation of humanized antibody. We are now proud to announce our partnership with TRIANNI, a biotech company specializing in antibody discovery technology, TAKIS is now able to provide fully human monoclonal antibodies for its clients.
TRIANNI’s lead technology, The Trianni Mouse™ enables efficient generation of fully-human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform.
Takis has a thorough experience in the development of monoclonal antibodies and the Trianni Mouse™ will be integrated with our antibody generation technologies, especially with in vivo electro-gene-transfer of plasmid DNA (DNA-EGT) vaccination technology, to provide our worldwide customers with an efficient platform for the discovery and development of fully human.
Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.